<DOC>
	<DOCNO>NCT02976259</DOCNO>
	<brief_summary>Sponsor : IMEA - Fondation Internationale Léon Mba C.H.U . Bichat - Claude Bernard 46 , Rue Henri Huchard - 75018 PARIS Tél . : 01.40 . 25 . 63 . 65 - Fax : 01.40.25.63.56 Coordinating investigator : Dr Caroline Lascoux Combe Hôpital Saint Louis Service Maladies Infectieuses 1 avenue Claude Vellefaux - 75010 PARIS Tél . : 01 42 49 49 73 - Fax : 01 42 49 47 43 E-mail : caroline.lascoux-combe @ aphp.fr Participating country : FRANCE Primary objective : Comparing kinetic HIV-RNA decay blood plasma seminal plasma patient start triple combination regimen dolutegravir + tenofovir DF ( TDF ) + emtricitabine ( FTC ) time PHI . Secondary objective : - Comparison HIV-1 RNA level plasma ( threshold 20 1 copies/ml ) seminal plasma ( threshold 60 copies/ml ) visit D0 , W2 , W4 , W8 , W12 , W24 , W36 , W48 - To assess frequency intermittent shed seminal plasma virological suppression achieve W48 - Evolution cellular HIV-1 DNA level PBMC non-sperm cell D0 W48 - Comparison dolutegravir concentration blood plasma seminal plasma - Study risk factor associate viral persistence HIV-RNA seminal plasma - Analysis deep sequence viral population ( quasi-species ) compartment ( blood plasma seminal plasma ) virological suppression achieve ( i.e . D0 W12 ) Inclusion criterion : - Patients diagnosed time primary HIV infection ( PHI ) ( ) negative indeterminate HIV ELISA associate positive antigenemia plasma HIV RNA , ( ii ) western blot profile compatible ongoing seroconversion ( incomplete western blot absence antibody pol protein ( p34 , p68 ) ) ( iii ) initially negative test HIV antibodies follow within 3 month positive HIV serology - Treatment include dolutegravir ( DTG 50mg ) + tenofovir/emtricitabine ( TDF/FTC 245 mg/200 mg ) initiate referee physician within maximum 15 day diagnosis PHI - Genotypic sensitivity TDF , FTC DTG - Patient medical care insurance Exclusion criterion : - Chronic infection - Infection co-infection HIV-2 Study treatment : Dolutegravir tenofovir/emtricitabine Number subjets : 20 patient ( exploratory study )</brief_summary>
	<brief_title>Kinetics HIV-RNA Decay Seminal Plasma Men Treated Dolutegravir Time Primary HIV Infection</brief_title>
	<detailed_description>Secondary objective : - Comparison HIV-1 RNA level plasma ( threshold 20 1 copies/ml ) seminal plasma ( threshold 60 copies/ml ) visit D0 , W2 , W4 , W8 , W12 , W24 , W36 , W48 - To assess frequency intermittent shed seminal plasma virological suppression achieve W48 - Evolution cellular HIV-1 DNA level PBMC non-sperm cell D0 W48 - Comparison dolutegravir concentration blood plasma seminal plasma - Study risk factor associate viral persistence HIV-RNA seminal plasma - Analysis deep sequence viral population ( quasi-species ) compartment ( blood plasma seminal plasma ) virological suppression achieve ( i.e . D0 W12 ) Inclusion criterion : - Patients diagnosed time primary HIV infection ( PHI ) ( ) negative indeterminate HIV ELISA associate positive antigenemia plasma HIV RNA , ( ii ) western blot profile compatible ongoing seroconversion ( incomplete western blot absence antibody pol protein ( p34 , p68 ) ) ( iii ) initially negative test HIV antibodies follow within 3 month positive HIV serology - Treatment include dolutegravir ( DTG 50mg ) + tenofovir/emtricitabine ( TDF/FTC 245 mg/200 mg ) initiate referee physician within maximum 15 day diagnosis PHI - Genotypic sensitivity TDF , FTC DTG - Patient medical care insurance Exclusion criterion : - Chronic infection - Infection co-infection HIV-2 Study treatment : Dolutegravir tenofovir/emtricitabine Number subjets : 20 patient ( exploratory study )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Patients diagnose time primary HIV infection ( PHI ) ( ) negative indeterminate HIV ELISA associate positive antigenemia plasma HIV RNA , ( ii ) western blot profile compatible ongoing seroconversion ( incomplete western blot absence antibody pol protein ( p34 , p68 ) ) ( iii ) initially negative test HIV antibodies follow within 3 month positive HIV serology Treatment include dolutegravir ( DTG 50mg ) + tenofovir/emtricitabine ( TDF/FTC 245 mg/200 mg ) initiate referee physician within maximum 15 day diagnosis PHI Genotypic sensitivity TDF , FTC DTG Patient medical care insurance Chronic infection Infection coinfection HIV2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>